Subramanya S. Rao
Experienced in Virilizing Ovarian Tumor

Dr. Subramanya S. Rao

Hematology | Oncology
12150 S Harlem Ave, 
Palos Heights, IL 
On Staff At
Offers Telehealth
Experienced in Virilizing Ovarian Tumor
12150 S Harlem Ave, 
Palos Heights, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Subramanya Rao is a Hematologist and an Oncologist in Palos Heights, Illinois. Dr. Rao is rated as an Experienced provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Paget Disease of the Breast, Pleuropulmonary Blastoma, Lung Cancer, and Myelodysplastic Syndrome (MDS).

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Residency
University of California Medical Center At Irvine, Internal Medicine
Specialties
Hematology
Oncology
Licenses
Internal Medicine in IL
Board Certifications
American Board Of Internal Medicine, Hematology
Fellowships
City of Hope National Medical Center, Hematology & Bone Marrow Transplant
Hospital Affiliations
Franciscan Health Olympia & Chicago Heights
Riverside Medical Center
Palos Community Hospital
Presence St Marys Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Celtic
  • HMO
  • INSURANCE PLAN
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Zing Health
  • MEDICARE MAPD
  • MEDICARE SNP
View 15 Less Insurance Carriers -

Locations

Affiliated Oncologists, LLC
12150 S Harlem Ave, Palos Heights, IL 60463
Other Locations
Affiliated Oncologists
10604 Southwest Hwy, Ste 109, Chicago Ridge, IL 60415
Affiliated Oncologists
82 Orland Square Dr, Orland Park, IL 60462

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Non-Hodgkin B-cell Lymphoma
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Non-Hodgkin B-cell Lymphoma
Enrollment Status: Withdrawn
Publish Date: February 25, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole, Goserelin, Leuprolide
Study Phase: Phase 3
Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
Enrollment Status: Terminated
Publish Date: August 18, 2022
Intervention Type: Drug
Study Drug: MT-3724
Study Phase: Phase 1/Phase 2
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS)
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS)
Enrollment Status: Completed
Publish Date: October 28, 2021
Intervention Type: Drug
Study Phase: Phase 3
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
Enrollment Status: Terminated
Publish Date: May 28, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

3 Total Publications

Zanubrutinib is well tolerated and effective in CLL/SLL patients intolerant of ibrutinib/acalabrutinib: Updated results.
Zanubrutinib is well tolerated and effective in CLL/SLL patients intolerant of ibrutinib/acalabrutinib: Updated results.
Journal: Blood advances
Published: December 02, 2024
Similar Doctors
Nikki L. Neubauer
Distinguished in Virilizing Ovarian Tumor
Dr. Nikki L. Neubauer
Oncology
Distinguished in Virilizing Ovarian Tumor
Dr. Nikki L. Neubauer
Oncology

Affiliated Oncologists, LLC

10604 Southwest Hwy, 
Chicago Ridge, IL 
 (40.2 miles away)
708-634-4644
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nikki Neubauer is an Oncologist in Chicago Ridge, Illinois. Dr. Neubauer is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Endometrial Cancer, Malignant Mixed Mullerian Tumor, Ovarian Cancer, Hernia Surgery, and Oophorectomy.

Alfred S. Guirguis
Distinguished in Virilizing Ovarian Tumor
Dr. Alfred S. Guirguis
Oncology
Distinguished in Virilizing Ovarian Tumor
Dr. Alfred S. Guirguis
Oncology

Affiliated Oncologists, LLC

10604 Southwest Hwy, 
Chicago Ridge, IL 
 (40.2 miles away)
708-634-4644
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alfred Guirguis is an Oncologist in Chicago Ridge, Illinois. Dr. Guirguis is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Endometrial Cancer, Endometrial Stromal Sarcoma, Malignant Mixed Mullerian Tumor, Hernia Surgery, and Oophorectomy.

Distinguished in Virilizing Ovarian Tumor
Dr. Mohamad Kassar
Hematology | Oncology
Distinguished in Virilizing Ovarian Tumor
Dr. Mohamad Kassar
Hematology | Oncology

Northwest Cancer Centers PC

1001 Calumet Ave, 
Dyer, IN 
 (33.1 miles away)
812-220-4476
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mohamad Kassar is a Hematologist and an Oncologist in Dyer, Indiana. Dr. Kassar is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Breast Cancer, Colorectal Cancer, Lynch Syndrome, Paget Disease of the Breast, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rao's expertise for a condition
ConditionClose
    View All 23 Advanced Conditions
    View All 82 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile